Dr. Gabriel Sosne To Present New Tβ4 Anti-Inflammation Data At ARVO
Dr. Sosne has also received a $60,000 Physician-Scientist Award by Research to Prevent Blindness (RPB), "for his groundbreaking work studying a molecule that may lead to the healing of damaged eyes." RPB is the world's leading voluntary organization supporting eye research. Since its founding, RPB has channeled hundreds of millions of dollars to medical institutions for research into the causes, treatment and the prevention of blinding eye diseases.
"Today there is nothing available, pharmacologically, that stimulates wound healing in the cornea. In cases of damage related to diabetes or alkaline exposure, treatments have focused on creating an environment conducive to healing," explained Dr. Sosne. "Thymosin Beta 4 may be the key to stimulating wound healing in the eye. It will change the way physicians treat eye injuries."
About RegeneRx Biopharmaceuticals, Inc.
RegeneRx is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Currently, RegeneRx is developing three drug products, RGN-137, RGN-259 and RGN-352 for dermal, ophthalmic, and cardiovascular wound healing, respectively. These drug products are based on Tβ4, a 43-amino acid peptide, in part, under an exclusive world-wide license from the National Institutes of Health. Preliminary research suggests that Tβ4 may prove efficacious for multiple indications; therefore, RegeneRx is developing several drug products as part of a broad therapeutic platform. RegeneRx holds over 60 world-wide patents and patent applications related to dermal, ocular, and internal wounds and tissue repair, cardiac and neurological protection and injuries, septic shock and several consumer product areas. RegeneRx is currently sponsoring three Phase II chronic dermal wound healing clinical trials, a Phase II ophthalmic wound healing clinical trial, and a Phase I parenteral clinical trial in support of systemic administration of Tβ4 for its cardiovascular clinical development program.
The RegeneRx Technology Platform
Tβ4 is a synthetic version of a naturally occurring peptide present in virtually all human cells. It is a first-in-class drug candidate that promotes endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition, and down-regulates inflammation. One of Tβ4's key mechanisms of action is its ability to regulate the cell-building protein, actin, a vital component of cell structure and movement. Of the thousands of proteins in cells, actin represents up to 10% of the total protein and, thus, plays a major role in the physiology of the cell. RegeneRx has identified several molecular variations of Tβ4 that may affect the aging of skin, among other properties, and could be important candidates as active ingredients in pharmaceutical and consumer products. Researchers at the National Institutes of Health, and at other academic institutions throughout the U.S., have published numerous scientific articles indicating that Tβ4 is effective in accelerating dermal and corneal wound healing in several animal models, under a variety of conditions. In two articles published in the scientific journal, Nature, researchers found that Tβ4 protects heart tissue following a myocardial infarction and can regenerate coronary vessels in laboratory animals. A recent abstract presented at an American Heart Association meeting showed that in a porcine model Tβ4 is cardio-protective after reperfusion following ischemic injury. Abstracts of scientific papers related to Tβ4's mechanisms of action may be viewed at RegeneRx's web page: http://www.regenerx.com.
Safe Harbor Statement
The information in this press release may include certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the Company's current expectations regarding future events, including the ongoing and prospective development of Tβ4 and possible future benefits to the Company, its shareholders, and patients. Due to the nature of product development and the regulatory approval process, the forward-looking statements are subject to risks and uncertainties, including those reflected in the Company's filings with the Securities and Exchange Commission, particularly its most recent Annual Report on Form 10-K. Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. The Company assumes no obligation to update or revise any forward-looking statements made herein or any other forward-looking statements made by the Company.
Regenerx Biopharmaceuticals
Dr. Gabriel Sosne de a prezenta noi T?4 anti-inflamaþie de date la ARVO - Dr. Gabriel Sosne To Present New Tβ4 Anti-Inflammation Data At ARVO - articole medicale engleza - startsanatate